2026 ICD-10-CM Diagnosis Code T49.5X5SAdverse effect of ophthalmological drugs and preparations, sequela

ICD-10-CM CodesS00–T88T36-T50T49

ICD-10-CM T49.5X5S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T49.5X5S is a billable ICD-10-CM diagnosis code for adverse effect of ophthalmological drugs and preparations, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T49.5X5S
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of ophthalmological drugs and preparations, sequela
Short Description
Adverse effect of opth drugs and preparations, sequela
Parent Code
Adverse effect of ophthalmological drugs and preparations

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT49Poisoning by, adverse effect of and underdosing of topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinorlaryngological and dental drugs
This CodeT49.5X5SAdverse effect of ophthalmological drugs and preparations, sequela

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T49.5X5S.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

T49.5X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Anticholinesterase parasympathomimetic adverse reaction
  • Cellulose-derived viscosity modifier adverse reaction
  • Corticosteroid-induced open angle glaucoma
  • Demecarium adverse reaction
  • Dipivefrine adverse reaction
  • Drug-induced ocular hypertension
  • Drug-induced open angle glaucoma
  • Drug-induced open angle glaucoma of bilateral eyes
  • Drug-induced open angle glaucoma of left eye
  • Drug-induced open angle glaucoma of right eye
  • Drug-induced uveitis
  • Ecothiopate adverse reaction
  • Hypromellose adverse reaction
  • Hypromellose eye drops adverse reaction
  • Lachesine chloride adverse reaction
  • Levobunolol adverse reaction
  • Metipranolol adverse reaction
  • Metipranolol-induced anterior uveitis
  • Ocular hypertension of left eye caused by corticosteroid
  • Ocular hypertension of right eye caused by corticosteroid
  • Open angle glaucoma of bilateral eyes caused by corticosteroid
  • Open angle glaucoma of left eye caused by corticosteroid
  • Open angle glaucoma of right eye caused by corticosteroid
  • Ophthalmological drug side effect
  • Ophthalmological monitoring status
  • Physostigmine adverse reaction
  • Prednisolone adverse reaction
  • Prednisolone drops adverse reaction
  • Secondary ocular hypertension caused by corticosteroid
  • Uveitis caused by ranibizumab
  • Viscosity modifier adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinorlaryngological and dental drugs (T49). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Levobunolol

    the l-isomer of bunolol.
  • Metipranolol

    a beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. it is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
  • Physostigmine

    a cholinesterase inhibitor that is rapidly absorbed through membranes. it can be applied topically to the conjunctiva. it also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
AmmoniumT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::acid tartrateT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::bromideT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::carbonateT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::chlorideT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::chloride::expectorantT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::compounds (household) NECT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::compounds (household) NEC::fumes (any usage)T49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::compounds (household) NEC::industrialT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::ichthyosulronateT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::mandelateT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::sulfamateT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ammonium::sulfonate resinT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
BefunololT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
BibrocatholT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
ChloropticT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Contact lens solutionT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Cycloplegic drugT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Demecarium (bromide)T49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
DendridT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
DipivefrineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Echothiophate, echothiopate, ecothiopateT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Ecothiopate iodideT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
EdoxudineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
EserineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
EucatropineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Eye agents (anti-infective)T49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Eye drug NECT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
FluorphenylalanineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
HerplexT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
HydroxyamphetamineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
HypromelloseT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
LachesineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
LevobunololT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Lubricant, eyeT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Methylparaben (ophthalmic)T49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
MetipranololT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Miotic drugT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Mydriatic drugT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
PhospholineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
PhysostigmineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
Propylparaben (ophthalmic)T49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
StoxilT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
TetrahydrozolineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
TetryzolineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6
VisineT49.5X1T49.5X2T49.5X3T49.5X4T49.5X5T49.5X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T49.5X5S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.5 Lte efct advrs efct drug
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E946.5 Adv eff eye anti-inf/drg
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T49.5X5SOverview

Is T49.5X5S (Adverse effect of ophthalmological drugs and preparations) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of ophthalmological drugs and preparations, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T49.5X5S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of ophthalmological drugs and preparations itself has resolved, not the original event.

What MS-DRG does T49.5X5S group to?

On inpatient claims, adverse effect of ophthalmological drugs and preparations, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T49.5X5S be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of ophthalmological drugs and preparations, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is T49.5X5S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of ophthalmological drugs and preparations, sequela on inpatient claims.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.